On the topic of vaccines vs anti-virals there is an illuminating article on the ABC Health Report of 27th April - http://www.abc.net.au/rn/healthreport/default.htm In short it questions the worth of vaccinating anyone, including "at risk groups" against seasonal flu, in what is probably the first statistically valid study of its kind. This does not mean a vaccine against a specific flu variant would not work but it does highlight the fact that (a) the influenza virus is quite different from all those other viruses that we have effective vaccinations against and (b) that anti-virals against influenza are our front line troops against any epidemic - especially a-v's that the virus has not yet evolved a defence against.
imo - The prospects for BTA - with Relenza and LANI are excellent. It is conceivable that by the time Relenza loses its patent protection, BTA will be sitting on excess of $250m of cash, partly franked - plus the prospect of its pipeline being close to monetisation.
BTA Price at posting:
$1.24 Sentiment: Buy Disclosure: Held
